Panacea Biotec

Panacea Biotec is a research-based health management company with a focus on pharmaceuticals, vaccines, and herbal products. Their product portfolio includes innovative prescription products in therapeutic areas like pain management, diabetes, cardiovascular, renal disease management, osteoporosis, and gastro-intestinal care. The company is also committed to disease prevention and reducing child mortality with their innovative vaccines. In the realm of vaccines, Panacea Biotec has introduced pioneering products such as the world's first fully liquid Hexavalent vaccine, EasySix (DTwP-Hib-HepB-IPV), and the first fully-liquid Pentavalent vaccine, Easyfive-TT (DTwP-Hib-HepB). They also have a high-impact pipeline of vaccines including Pneumococcal conjugate vaccines and tetravalent dengue vaccine. In the pharmaceutical sector, the company has commercialized Sitcom, a leading product in the treatment of Haemorrhoids and Piles, as well as other leading brands like Pangraf, Mycept, Glizid, Livoluk, and PacliAll, catering to the fields of transplantation, diabetes, constipation, and oncology. Panacea Biotec's facilities are WHO Prequalified, US FDA approved, and cGMP compliant, and their products are available in over 145 countries, including the US and Germany. Since its establishment in 1994, the company has supplied billions of immunizations and has garnered the trust of organizations such as WHO, GAVI, and UNICEF.